Holger Siebeneicher

USPTO Granted Patents = 14 (Patent Applications = 14)

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 8.4

ph-index = 5

Forward Citations = 65(Granted Patents)

Company Filing History:

10 out of 378

Bayer Pharma Aktiengesellschaft

Bayer Pharma Aktiengessellschaft

patents

4. 1 out of 12,157

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12006304 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

2. 12006303 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

3. 11319324 - Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors (2022-05-03),

4. 10793545 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2020-10-06),

5. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

6. 10435396 - 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs (2019-10-08),

7. 10308634 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2019-06-04),

8. 10167293 - [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones (2019-01-01),

9. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

10. 9951086 - Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments (2018-04-24),

11. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

12. 9744252 - Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi (2017-08-29),

13. 9345793 - Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi (2016-05-24),

14. 8968701 - Usage of low to medium-pressure liquid chromatography for the purification of radiotracers (2015-03-03),

Title: Holger Siebeneicher: Innovator in Pharmaceutical Chemistry

Introduction

Holger Siebeneicher is a prominent inventor based in Berlin, Germany, known for his significant contributions to pharmaceutical chemistry. With a total of 14 patents to his name, he has made remarkable advancements in the field of drug development.

Latest Patents

His latest patents focus on substituted indazoles, which are novel compounds with potential therapeutic applications. These patents detail methods for the production of these compounds, as well as pharmaceutical preparations that incorporate them. The applications highlight the use of substituted indazoles in treating various diseases, including endometriosis, rheumatoid arthritis, multiple sclerosis, and several other conditions. The innovative approaches outlined in his patents aim to improve treatment outcomes for patients suffering from these ailments.

Career Highlights

Throughout his career, Holger Siebeneicher has worked with notable companies such as Bayer Pharma and Piramal Imaging. His experience in these organizations has allowed him to develop and refine his expertise in pharmaceutical research and development.

Collaborations

Holger has collaborated with esteemed colleagues, including Holger Steuber and Ulrich Bothe, contributing to a dynamic exchange of ideas and innovations in the field.

Conclusion

Holger Siebeneicher's work in pharmaceutical chemistry exemplifies the impact of innovative thinking on drug development. His contributions continue to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.